Reported Earnings • Jul 02
Second quarter 2026 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 2Q 2025) Second quarter 2026 results: CA$0.002 loss per share (in line with 2Q 2025). Revenue: CA$190.5k (down 78% from 2Q 2025). Net loss: CA$276.9k (loss widened 34% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Anuncio • Jun 30
RAMM Pharma Corp., Annual General Meeting, Aug 28, 2026 RAMM Pharma Corp., Annual General Meeting, Aug 28, 2026. Board Change • Jun 29
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 04
First quarter 2026 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 1Q 2025) First quarter 2026 results: CA$0.006 loss per share (improved from CA$0.009 loss in 1Q 2025). Revenue: CA$212.7k (down 79% from 1Q 2025). Net loss: CA$758.5k (loss narrowed 26% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 06
Full year 2025 earnings released: CA$0.075 loss per share (vs CA$0.14 loss in FY 2024) Full year 2025 results: CA$0.075 loss per share (improved from CA$0.14 loss in FY 2024). Revenue: CA$3.36m (down 23% from FY 2024). Net loss: CA$8.91m (loss narrowed 46% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Board Change • Oct 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 28
Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.008 loss in 3Q 2024) Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.008 loss in 3Q 2024). Revenue: CA$883.2k (down 27% from 3Q 2024). Net loss: CA$523.1k (loss narrowed 47% from 3Q 2024). Board Change • Aug 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 01
Second quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.015 loss in 2Q 2024) Second quarter 2025 results: CA$0.002 loss per share (improved from CA$0.015 loss in 2Q 2024). Revenue: CA$861.6k (down 26% from 2Q 2024). Net loss: CA$207.3k (loss narrowed 88% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Anuncio • Jun 30
RAMM Pharma Corp., Annual General Meeting, Aug 29, 2025 RAMM Pharma Corp., Annual General Meeting, Aug 29, 2025. Board Change • Jun 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jun 10
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • May 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 01
First quarter 2025 earnings released: CA$0.009 loss per share (vs CA$0.019 loss in 1Q 2024) First quarter 2025 results: CA$0.009 loss per share (improved from CA$0.019 loss in 1Q 2024). Revenue: CA$1.01m (up 5.7% from 1Q 2024). Net loss: CA$1.02m (loss narrowed 55% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 61% per year, which means it is performing significantly worse than earnings. Board Change • Mar 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Anuncio • Dec 12
RAMM Pharma Corp. Provides Update on Litigation RAMM Pharma Corp. is providing an update on its dispute with Sergio Martines and Naturale Science Inc. (plaintiffs), as previously reported in its press release of May 21st 2024. The Judge has dismissed the plaintiffs’ claim in the amount of CAD 3,139,931.30 and has awarded Martines CAD 14,971.80 in unpaid expenses. The Judge has also dismissed RAMM’s counterclaim in the amount of CAD 14,220,000. Reasons for Judgement, published on December 9th, 2024, may be accessed at the Ontario Superior Court of Justice website. Reported Earnings • Sep 29
Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2023) Third quarter 2024 results: CA$0.008 loss per share (improved from CA$0.009 loss in 3Q 2023). Revenue: CA$1.21m (down 9.2% from 3Q 2023). Net loss: CA$993.8k (loss narrowed 4.3% from 3Q 2023). Reported Earnings • Jun 30
Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.01 loss in 2Q 2023) Second quarter 2024 results: CA$0.015 loss per share (further deteriorated from CA$0.01 loss in 2Q 2023). Revenue: CA$1.16m (down 8.1% from 2Q 2023). Net loss: CA$1.73m (loss widened 48% from 2Q 2023). Anuncio • Jun 13
RAMM Pharma Corp., Annual General Meeting, Aug 09, 2024 RAMM Pharma Corp., Annual General Meeting, Aug 09, 2024. New Risk • Mar 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$4.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.5m free cash flow). Shares are highly illiquid. Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (CA$7.16m market cap, or US$5.29m). Minor Risk Revenue is less than US$5m (CA$4.7m revenue, or US$3.5m). Reported Earnings • Mar 01
Full year 2023 earnings released: CA$0.064 loss per share (vs CA$0.17 loss in FY 2022) Full year 2023 results: CA$0.064 loss per share (improved from CA$0.17 loss in FY 2022). Revenue: CA$5.07m (up 30% from FY 2022). Net loss: CA$7.72m (loss narrowed 63% from FY 2022). New Risk • Oct 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 34% per year over the past 5 years. Market cap is less than US$10m (CA$8.36m market cap, or US$6.15m). Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (CA$5.1m revenue, or US$3.8m). New Risk • Oct 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 34% per year over the past 5 years. Market cap is less than US$10m (CA$11.8m market cap, or US$8.72m). Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (CA$5.1m revenue, or US$3.8m). Reported Earnings • Sep 30
Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.009 loss in 3Q 2022) Third quarter 2023 results: CA$0.009 loss per share (in line with 3Q 2022). Revenue: CA$1.33m (up 50% from 3Q 2022). Net loss: CA$1.04m (loss narrowed 9.2% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Board Change • Sep 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jul 29
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jun 29
Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.012 loss in 2Q 2022) Second quarter 2023 results: CA$0.01 loss per share (improved from CA$0.012 loss in 2Q 2022). Revenue: CA$1.26m (up 44% from 2Q 2022). Net loss: CA$1.17m (loss narrowed 19% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 09
First quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.016 loss in 1Q 2022) First quarter 2023 results: CA$0.014 loss per share (improved from CA$0.016 loss in 1Q 2022). Revenue: CA$1.33m (up 41% from 1Q 2022). Net loss: CA$1.66m (loss narrowed 14% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Board Change • Mar 31
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 03
Full year 2022 earnings released: CA$0.17 loss per share (vs CA$0.066 loss in FY 2021) Full year 2022 results: CA$0.17 loss per share (further deteriorated from CA$0.066 loss in FY 2021). Revenue: CA$3.90m (down 5.3% from FY 2021). Net loss: CA$21.0m (loss widened 195% from FY 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Board Change • Feb 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Daniel Augereau was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 30
Third quarter 2022 earnings released: CA$0.009 loss per share (vs CA$0.03 loss in 3Q 2021) Third quarter 2022 results: CA$0.009 loss per share (improved from CA$0.03 loss in 3Q 2021). Net loss: CA$1.14m (loss narrowed 63% from 3Q 2021). Reported Earnings • Jun 29
Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.004 loss in 2Q 2021) Second quarter 2022 results: CA$0.012 loss per share (down from CA$0.004 loss in 2Q 2021). Net loss: CA$1.44m (loss widened 238% from 2Q 2021). Board Change • Apr 27
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Eric Klein is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 24
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Eric Klein is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Anuncio • Feb 05
RAMM Pharma Corp., Annual General Meeting, Apr 07, 2022 RAMM Pharma Corp., Annual General Meeting, Apr 07, 2022. Board Change • Dec 06
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Eric Klein is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 01
Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.018 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$999.3k (up 1.4% from 3Q 2020). Net loss: CA$3.12m (loss widened 76% from 3Q 2020). Reported Earnings • Jul 02
Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.012 loss in 2Q 2020) The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: CA$1.06m (down 45% from 2Q 2020). Net loss: CA$425.5k (loss narrowed 66% from 2Q 2020). Anuncio • May 14
RAMM Pharma Corp. (CNSX:RAMM) agreed to acquire the remaining 51% stake in Canapar S.r.L. for approximately $26.2 million. RAMM Pharma Corp. (CNSX:RAMM) agreed to acquire the remaining 51% stake in Canapar S.r.L. for approximately $26.2 million on May 11, 2021. On closing of the Transaction, Sergio Martines, the current Chief Executive Officer of Canapar, will be appointed to the board of directors of RAMM. Martines will also be appointed to the senior management team of the Company and will keep the position of Chief Executive Officer of Canapar Corp. The transaction is subject to standard closing conditions, and the approval of the shareholders of Canapar. Anuncio • May 01
Jack Burnett, President and a director of Ramm Pharma, Daniel Augereau, a director of Ramm Pharma and an unknown buyer acquired approximately 10% stake in RAMM Pharma Corp. (CNSX:RAMM) from Armando Blankleider for CAD 2.3 million. Jack Burnett, President and a director of Ramm Pharma, Daniel Augereau, a director of Ramm Pharma and an unknown buyer acquired approximately 10% stake in RAMM Pharma Corp. (CNSX:RAMM) from Armando Blankleider for CAD 2.3 million on April 27, 2021. Armando Blankleider sold an aggregate of 10,000,000 common shares in a number of private sale arrangements at a price of CAD 0.23 per common share. Immediately prior to the disposition of the Common Shares pursuant to the Share Dispositions, Armando Blankleider beneficially owned or controlled 19,671,500 Common Shares, representing approximately 19.7% of the issued and outstanding Common Shares on a non-diluted basis. As at the date hereof, Armando beneficially owns or controls an aggregate amount of 9,671,500 Common Shares representing approximately 9.7% of the issued and outstanding Common Shares on a non-diluted basis. The proceeds from the sale of the Common Shares sold by Armando were used to fund the repayment of an existing debt.
Jack Burnett, President and a director of Ramm Pharma, Daniel Augereau, a director of Ramm Pharma and an unknown buyer completed the acquisition of approximately 10% stake in RAMM Pharma Corp. (CNSX:RAMM) from Armando Blankleider on April 27, 2021. Reported Earnings • Apr 02
First quarter 2021 earnings released: CA$0.015 loss per share (vs CA$0.02 loss in 1Q 2020) The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: CA$1.01m (down 23% from 1Q 2020). Net loss: CA$1.45m (loss narrowed 29% from 1Q 2020). Is New 90 Day High Low • Mar 12
New 90-day high: CA$1.14 The company is up 153% from its price of CA$0.45 on 11 December 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 41% over the same period. Reported Earnings • Mar 03
Full year 2020 earnings released: CA$0.074 loss per share (vs CA$0.14 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: CA$5.44m (down 3.0% from FY 2019). Net loss: CA$7.43m (loss widened 8.9% from FY 2019). Anuncio • Feb 24
RAMM Pharma Selects as COVID-19 Vaccine Fulfilment & Distribution Partner by the Uruguayan Ministry of Health RAMM Pharma Corp. announced that the Uruguayan Ministry of Public Health, (Ministerio de Salúd Publica or “MSP”) has selected RAMM as a fulfilment and distribution partner for Uruguay’s COVID-19 vaccination program. Under the arrangement, RAMM will be responsible for the sterilization, packaging and distribution of syringes and other medical supplies for use in the country’s COVID-19 vaccination program. RAMM’s GMP certified pharmaceutical facility was selected for the program upon satisfaction of the stringent requirements of the Ministry of Public Health. RAMM's wholly owned, GMP certified formulation facility is ideally situated within close proximity to an airport and other distribution hubs. The facility totals approximately 36,600 square feet and features dedicated cannabis and medical product laboratories, along with sterilization and packaging capabilities and storage/distribution facilities. RAMM is an essential provider of medical and pharmaceutical products for the healthcare industry. Since it’s inception in 1988, RAMM’s wholly owned subsidiary Medic Plast SA has manufactured and supplied medical devices, antiseptic and sterile products and other medical supplies and continues to be a strategic supplier to the medical community in Uruguay. With a current portfolio of over 150 products registered with the Ministry of Health, Medic Plast is an established leader in the Uruguayan market for sales of recognized quality products under the BIOSET brand, including alcohol-based hand sanitizer and antiseptic soaps, sterile hospital devices and sterilization equipment, syringes and various other surgical and medical supplies. Is New 90 Day High Low • Feb 10
New 90-day high: CA$1.05 The company is up 110% from its price of CA$0.50 on 10 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 92% over the same period. Anuncio • Jan 22
Canapar Corp. and RAMM Pharma Corp. enters into Strategic Partnership Canapar Corp. and RAMM Pharma Corp. announced that they have entered into a strategic partnership, combining Canapar’s hemp-derived cannabidiol extraction expertise with RAMM’s leadership in cannabis-derived pharmaceutical and cosmeceutical products. As part of the strategic partnership, RAMM has acquired Canopy Rivers’ 49% ownership interest in Canapar. This investment is expected to immediately enhance both RAMM and Canapar’s ability to capitalize on the rapidly expanding European and South American hemp-derived CBD markets. Is New 90 Day High Low • Jan 21
New 90-day high: CA$0.75 The company is up 21% from its price of CA$0.62 on 19 October 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 73% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: CA$0.68 The company is up 24% from its price of CA$0.55 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 55% over the same period. Is New 90 Day High Low • Nov 03
New 90-day low: CA$0.45 The company is down 18% from its price of CA$0.55 on 05 August 2020. The Canadian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Anuncio • Oct 10
Ramm Pharma Corp. Commences Sales of Epifractán Products Through Peruvian Pharmacies RAMM Pharma Corp. announced that the Company has commenced sales of its Epifractán™ products through Peruvian pharmacies. As announced on July 9th and 16th, 2020, Epifractán™ was approved and registered by Peru’s Ministry of Health (Ministerio de Salud or “MINSA”), becoming one of only a few cannabis products registered in the country. Both Epifractán™ 2% and Epifractán™ 5% have now been shipped to Peru for sale through pharmacies and will be available to patients with a medical prescription. RAMM also continues to scale up regular shipments of Epifractán™ to Brazil under the country’s compassionate use framework. Epifractán™ was approved and registered in Peru upon the completion of rigorous testing requirements and approval by MINSA to certify consistency, stability and effective shelf life. Registered products are available at pharmacies as branded finished products and should not be confused with magistral formulas which are prepared by a pharmacist on a case-by-case basis and have not received MINSA approval and registration. Currently only very few cannabidiol products have been granted MINSA registration in Peru. Reported Earnings • Oct 01
Third quarter earnings released Over the last 12 months the company has reported total losses of CA$9.88m, with losses widening by 87% from the prior year. Total revenue was CA$5.57m over the last 12 months, down 12% from the prior year. 
